FDA Has Extended the Comment Period For Its Draft Biosimilar Labeling Guidance

The FDA has extended the public comment period for its draft guidance “Labeling for Biosimilar Products: Guidance for Industry” by 60 days, to August 2, 2016:

https://www.federalregister.gov/articles/2016/06/06/2016-13223/labeling-for-biosimilar-products-draft-guidance-for-industry-availability-extension-of-comment

The post FDA Has Extended the Comment Period For Its Draft Biosimilar Labeling Guidance appeared first on Big Molecule Watch.